RALEIGH, N.C., Oct. 16 /PRNewswire/ -- CLOSURE Medical Corporation
(Nasdaq: CLSR), a medical tissue adhesive products company, today announced
that it intends to release, on Tuesday, October 23, 2001, financial results
for the third quarter ended September 30, 2001 and an outlook of the Company's
expectations for 2002. In conjunction with this release CLOSURE will host a
conference call that will be broadcast simultaneously live over the Internet.
Individuals wishing to participate on the webcast, to be held at 4:30 PM
ET on Tuesday, October 23, 2001, can access the event at
http://www.closuremed.com . Please allow extra time prior to the call to
download the streaming media software required for listening to the Internet
broadcast. The online archive of the broadcast will be available within 2
hours of the live call and will be available for replay.
CLOSURE Medical Corporation, headquartered in Raleigh, North Carolina,
develops, manufactures, and commercializes medical tissue adhesive products
based on its proprietary cyanoacrylate technology. CLOSURE's proprietary
technology has customized the physical and chemical properties of
cyanoacrylates to develop medical adhesive formulations to close and seal
topical skin wounds and incisions, as well as formulations to close or seal
internal wounds.
Currently marketed nonabsorbable tissue adhesive products include:
DERMABOND Topical Skin Adhesive, which is used to replace sutures and staples
for closure of certain lacerations and incisions; SOOTHE-N-SEAL(TM) canker
sore relief, an over-the-counter ("OTC") product to treat oral ulcers and
mouth sores; and NEXABAND(R) topical adhesives used in veterinary wound
closure and wound care. In addition to its currently marketed products,
CLOSURE's LIQUIDERM(TM) liquid adhesive bandage is the first and only
cyanoacrylate medical device approved by the FDA for the OTC adhesive bandage
market. CLOSURE has entered into a definitive agreement providing Johnson &
Johnson Consumer Products Company with supply, distribution and development
rights to its LIQUIDERM(TM) adhesive with the product launch expected to occur
in early 2002. CLOSURE is also developing internal adhesives for wound
closure and the possible treatment of emphysema, as well as developing liquid
occlusive dressings for the treatment of a variety of partial thickness
wounds, including pressure ulcers and skin tears.
DERMABOND adhesive is a registered trademark of Ethicon, Inc.; SOOTHE-N-
SEAL(TM) is a licensed trademark of Colgate Oral Pharmaceuticals, Inc.;
LIQUIDERM(TM) is a trademark of CLOSURE Medical Corporation; and NEXABAND(R)
is a registered trademark of CLOSURE Medical Corporation.
To receive CLOSURE's latest news release and other corporate documents
visit the Financial Relations Board's website at http://www.frbinc.com .
This release contains certain forward-looking statements which involve
known and unknown risks, delays, uncertainties or other factors not under the
Company's control which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance, or
other expectations implied by these forward-looking statements. These factors
include, but are not limited to the early stage of commercialization of the
Company products; the progress of its research and development programs for
future products; the need for regulatory approval and effects of governmental
regulation; technological uncertainties; the satisfactory conclusion of
negotiations with, and dependence on marketing partners, and dependence on
patents and trade secrets, as well as those detailed in the Company's Annual
Report on Form 10-K for the year ended December 31, 2000 filed with the
Securities and Exchange Commission.
SOURCE CLOSURE Medical Corporation
 back to top
Related links:
http://www.frbinc.com
http://www.closuremed.com
CONTACT:
Robert V. Toni, President & CEO, or Benny
Ward, CFO of CLOSURE Medical Corporation, +1-919-876-7800, or
General, Alison Ziegler, Analysts, Julie Tu, or Media, Judith
Sylk-Siegel, of FRB Weber Shandwick, +1-212-445-8400
|
